Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.52 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 3/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194934 | 0.87 | FAAH (0.63) | FAAHSGMS2F10LRRK2F2 | |
| Hydrochloric Acid SCHEMBL2197108 | 0.86 | FAAH (0.62) | FAAHSGMS2F10LRRK2F2 | |
| SCHEMBL12508794 | 0.86 | FAAH (0.58) | FAAHSGMS2F10LRRK2F2 | |
| SCHEMBL12509210 | 0.86 | FAAH (0.63) | FAAHSGMS2F10LRRK2F2 | |
| SCHEMBL12508786 | 0.86 | F10 (0.55) | FAAHSGMS2F10LRRK2F2 | |
| SCHEMBL12509358 | 0.84 | FAAH (0.53) | FAAHSGMS2F10LRRK2F2 | |
| SCHEMBL12508494 | 0.84 | FAAH (0.51) | FAAHSGMS2F10LRRK2F2 | |
| SCHEMBL12509156 | 0.84 | FAAH (0.58) | FAAHSGMS2F10LRRK2F2 | |
| SCHEMBL12509154 | 0.84 | FAAH (0.58) | FAAHSGMS2F10LRRK2MEN1 | |
| SCHEMBL12508496 | 0.83 | FAAH (0.51) | FAAHSGMS2F10LRRK2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | FAAH 1/4885SGMS2 720/4885F10 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.